Bayer AG and Cedilla Therapeutics Inc. have entered into an exclusive license agreement to develop and commercialize Cedilla Therapeutics' cyclinE1/cyclin dependent kinase 2 (CDK2) complex inhibitors, which selectively address oncogenic drivers.